Eli Lilly announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference, highlighting new clinical evidence on Kisunla (donanemab-azbt), including long-term safety and biomarker data. The company also shared promising results comparing P-tau217 blood tests to amyloid PET scans for early Alzheimer's detection in cognitively unimpaired individuals, suggesting a more accessible diagnostic option. These findings underscore Lilly's 35-year commitment to advancing Alzheimer's research and treatment. Presentations will be available online after the conference in London from July 12-15, 2026.
Eli Lilly reported strong sales growth for its drugs Mounjaro, Jaypirca, and Omvoh, with Jaypirca sales up 56.4% year-on-year to $192 million in Q2 despite competition. The company’s Retatrutide showed promising results in obesity trials, potentially...
Novo Nordisk CEO Mike Doustdar highlighted the early stage of GLP-1 drug adoption for obesity treatment, noting that over 100 million Americans suffer from obesity but only about 10-15% have used these medications. He emphasized the potential for the...
Novo Nordisk has received a "Sell" rating due to growing competition from Eli Lilly and internal challenges like expiring patents and manufacturing issues. An analyst set a cautious price target of $47, reflecting concerns over flat to negative growt...
Eli Lilly has filed six new lawsuits against U.S. entities selling unapproved retatrutide, an investigational drug still in Phase 3 trials for obesity and diabetes. The company warns that black-market retatrutide is unsafe and illegal, urging regulat...
Eli Lilly reported a strong second quarter with revenue of $22.97 billion, surpassing expectations, and earnings per share (EPS) of $8.38, beating consensus by over 27%. The growth was driven by a 91% increase in sales of its obesity drug Mounjaro, b...
